Clinical trials: Neoplasm Metastases
Liver Metastases, Non-Small Cell Lung Cancer
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
This study aims to evaluate the effectiveness and safety of combining low-dose radiotherapy to the intestines with immune checkpoint inhibitors (ICIs) in patients with liver metastases from solid tumors.
- Conditions
- Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic
- Trial name
- ILDR-ICI-LM (NCT07875465)
- Testing
- Intestinal Low-Dose Radiotherapy (ILDR), PD-1/PD-L1 inhibitors, Combined Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bing Xia
Prostate Cancer, Prostatic Neoplasms
Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this observational study is to learn which factors can predict how well lutetium-177 PSMA therapy works in people with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastases
- Trial name
- NCT07863986
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry
- Where
- Lithuania
- Volunteers
- 70 people
- Sponsor
- Lithuanian University of Health Sciences
Estrogen Receptor Positive Breast Cancer, Bone Metastases
FDG PET/CT in Breast Cancer Bone Mets
This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and…
- Trial name
- NCT01996046
- Testing
- FDG PET/CT scan
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Bone Metastases in Subjects With Advanced Cancer
SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue
This is a randomized, controlled, prospective phase II, two-arm clinical study designed to evaluate the efficacy and safety of using either Spatially Fractionated Radiotherapy (SFRT) or Stereotactic Central Ablative Radiotherapy…
- Trial name
- NCT06987370
- Testing
- Conventional Radiotherapy (CRT), SCART (Stereotactic Central Ablative Radiation Therapy ) /SFRT（Spatially Fractionated Radiation Therapy ）
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shandong Cancer Hospital and Institute
HER2-positive Advanced Breast Cancer, Brain Metastases
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined…
- Conditions
- HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT07100600
- Testing
- Trastuzumab Rezetecan, FSRT or WBRT
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital
Liver Metastases, Hepatic Metastases
Therapeutic Efficacy and Safety of Ultrasound-Guided Microwave Ablation for Hepatic Metastatic Nodules
The liver is one of the most common organs where cancer cells spread (metastasize) from other parts of the body, especially from gastrointestinal cancers such as colorectal cancer.
- Conditions
- Liver Metastases, Hepatic Metastases, Secondary Malignant Neoplasm of Liver, Colorectal Cancer Metastatic
- Trial name
- NCT07871253
- Testing
- Ultrasound-Guided Microwave Ablation
- Volunteers
- 30 people
- Sponsor
- Assiut University
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Bone Metastases, Metastatic Solid Tumor
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers
This is a prospective, randomized, single-center clinical trial evaluating whether early prophylactic radiotherapy to high-risk asymptomatic or minimally symptomatic bone metastases reduces the 1-year rate of skeletal-related…
- Trial name
- pRevenT (NCT07540650)
- Testing
- Prophylactic External Beam Radiotherapy, Standard of Care
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- Institute of Oncology Ljubljana
Extensive-stage Small-cell Lung Cancer, Liver Metastases
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer…
- Trial name
- BELIEVE (NCT05588388)
- Testing
- Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Kamya Sankar
Small-cell Lung Cancer, Brain Metastases
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the…
- Conditions
- Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
- Trial name
- SHARP (NCT06457906)
- Testing
- Experimental group (SRS/SRT/Hypo-RT), Controled group (HA-WBRT)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brain Metastases, Adult, Breast Cancer
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast…
- Trial name
- BEAT-Breast (NCT06611306)
- Testing
- DE-iPTV
- Where
- 2 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Brain Metastases, Tumor
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases.
- Trial name
- NCT05064280
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Brain Metastases
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic…
- Trial name
- NCT06649058
- Testing
- Systemic Therapy, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic, Brain Metastases, Adult
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
GENCONCOR-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (BM) of colorectal cancer (CRC).
- Conditions
- Colorectal Cancer Metastatic, Brain Metastases, Adult, Ras (KRAS or NRAS) Gene Mutation, BRAF Gene Mutation
- Trial name
- GENCONCOR-1 (NCT06449989)
- Testing
- Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Colorectal Cancer, Peritoneal Metastases
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
- Conditions
- Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
- Trial name
- NCT07411599
- Testing
- Cyclophosphamide, Fludarabine, Cetuximab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, Esophageal Cancer
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
GENCONCOR-2 is a translational research aimed to compare the molecular profile of primary tumors and their matched brain metastases in gastroesophageal cancers, including cancer of the esophagus, gastroesophageal junction, and…
- Conditions
- Gastric Cancer, Esophageal Cancer, Brain Metastases
- Trial name
- GENCONCOR-2 (NCT07464470)
- Testing
- HER2 Testing, MSI Testing, PD-L1 Testing
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Liver Metastases, Liver Neoplasms
Non-Contrast Versus Contrast-Enhanced MRI in Colorectal Liver Metastases
This prospective study aims to compare the diagnostic performance of a non-contrast abbreviated MRI protocol with a contrast-enhanced MRI protocol for the detection and follow-up assessment of colorectal liver metastases.
- Trial name
- NCT07857317
- Volunteers
- 40 people
- Sponsor
- Assiut University
Colorectal Cancer, Liver Metastases
Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
Patients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor prognosis. In patients with resectable disease, surgery offers a distinct survival benefit.
- Trial name
- NCT02864485
- Testing
- live donor liver transplantation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto